Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.31 -0.8%	$10.40	$3.85 ▼ $12.43	$1.57B	1.83	1.64 million shs	1.50 million shs
CYDY CytoDyn	$0.30 -4.9%	$0.33	$0.10 ▼ $0.49	$394.98M	1.17	1.42 million shs	2.68 million shs
ETNB 89BIO	$10.11 -3.6%	$9.79	$4.16 ▼ $11.84	$1.53B	1.28	1.53 million shs	1.21 million shs
WVE WAVE Life Sciences	$7.87 -5.6%	$6.85	$5.04 ▼ $16.74	$1.30B	-1.01	1.33 million shs	1.99 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-0.77%	-10.74%	-0.67%	+47.08%	+155.20%
CYDY CytoDyn	-4.58%	-5.90%	-3.23%	+39.53%	+110.53%
ETNB 89BIO	-3.62%	-9.08%	+0.30%	+54.35%	+21.08%
WVE WAVE Life Sciences	-5.64%	+0.38%	+19.79%	+19.97%	+34.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.9544 of 5 stars	1.4	1.0	0.0	4.2	3.2	2.5	0.6
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	1.7659 of 5 stars	3.5	1.0	0.0	0.0	2.0	0.8	0.6
WVE WAVE Life Sciences	4.6362 of 5 stars	3.5	2.0	0.0	4.8	3.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	2.54% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
ETNB 89BIO	3.00	Buy	$26.43	161.41% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.15	156.08% Upside

Current Analyst Ratings Breakdown

Latest CYDY, ADPT, ETNB, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	8.26	N/A	N/A	$1.37 per share	7.53
CYDY CytoDyn	N/A	N/A	N/A	N/A	($0.11) per share	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
WVE WAVE Life Sciences	$104.94M	11.67	N/A	N/A	$1.37 per share	5.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	8/5/2025 (Estimated)
CYDY CytoDyn	-$49.84M	N/A	0.00	∞	N/A	N/A	N/A	-33.26%	8/13/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/14/2025 (Estimated)

Latest CYDY, ADPT, ETNB, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	WVE WAVE Life Sciences	-$0.28	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
CYDY CytoDyn	N/A	0.30	0.30
ETNB 89BIO	0.06	18.03	18.03
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CYDY CytoDyn	5.06%
ETNB 89BIO	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
CYDY CytoDyn	0.54%
ETNB 89BIO	2.80%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.24 billion	Not Optionable
ETNB 89BIO	40	145.98 million	141.90 million	Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

CYDY, ADPT, ETNB, and WVE Headlines

Recent News About These Companies

Hussman Strategic Advisors Inc. Has $848,000 Stake in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 19 at 8:01 AM | marketbeat.com

Principal Financial Group Inc. Acquires 59,399 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 19 at 3:08 AM | marketbeat.com

Breaking Down WAVE Life Sciences: 4 Analysts Share Their Views

July 16, 2025 | benzinga.com

Citigroup Initiates Coverage of Wave Life Sciences (WVE) with Buy Recommendation

July 16, 2025 | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Should You Buy?

July 16, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Coverage Initiated at Citigroup

July 16, 2025 | marketbeat.com

Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions

July 15, 2025 | msn.com

WAVE Life Sciences (NASDAQ:WVE) Shares Down 6.5% - What's Next?

July 15, 2025 | marketbeat.com

Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24

July 11, 2025 | msn.com

NASDAQ:WVE Financials | Wave Life Sciences Ltd - Investing.com

July 11, 2025 | investing.com

WAVE Life Sciences (NASDAQ:WVE) Trading Up 6.8% - Should You Buy?

July 9, 2025 | marketbeat.com

WAVE Life Sciences Ltd. Company & People | WVE | Barron's

July 7, 2025 | barrons.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

July 7, 2025 | seekingalpha.com

Wave Life Sciences: Speculative, But Promising

July 7, 2025 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) - Yahoo Finance

July 6, 2025 | finance.yahoo.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages

July 6, 2025 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4, 2025 | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3, 2025 | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYDY, ADPT, ETNB, and WVE Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.31 -0.08 (-0.77%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$10.47 +0.16 (+1.51%)

As of 07:00 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

CytoDyn OTCMKTS:CYDY

$0.30 -0.02 (-4.94%)

As of 07/21/2025 03:57 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

89BIO NASDAQ:ETNB

$10.11 -0.38 (-3.62%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$10.12 +0.01 (+0.05%)

As of 07/21/2025 04:54 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

WAVE Life Sciences NASDAQ:WVE

$7.87 -0.47 (-5.64%)

Closing price 07/21/2025 04:00 PM Eastern

Extended Trading

$8.00 +0.13 (+1.70%)

As of 07:15 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time